Evidence map›Paper›PMID 40742365›Full record

ArticleJACC. Basic to translational science2025

Novel Method for Predicting Lp(a) From Genomic Testing Identifies ASCVD Risk Across a Diverse Cohort.

Natalie Telis, Hang Dai, Ashley Waring, David Kann, Dana Wyman, Simon White, Basil Khuder, Francisco Tanudjaja, Alexandre Bolze, Matthew E Levy and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. Basic to translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Genetic Prediction of Circulating Lipoprotein(a) Levels in Diverse Populations.medRxiv : the preprint server for health sciences · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Natalie TelisDivision of Research, Helix Opco, San Mateo, California, USA. Electronic address: natalie.telis@helix.com.
Hang DaiDivision of Research, Helix Opco, San Mateo, California, USA.
Ashley WaringDivision of Cardiovascular Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.
David KannDepartment of Pathology and Laboratory Medicine, St. Luke's University Health Network, Bethlehem, Pennsylvania, USA.
Dana WymanDivision of Research, Helix Opco, San Mateo, California, USA.
Simon WhiteDivision of Research, Helix Opco, San Mateo, California, USA.
Basil KhuderDivision of Research, Helix Opco, San Mateo, California, USA.
Francisco TanudjajaDivision of Research, Helix Opco, San Mateo, California, USA.
Alexandre BolzeDivision of Research, Helix Opco, San Mateo, California, USA.
Matthew E LevyDivision of Research, Helix Opco, San Mateo, California, USA.
Cassie HajekDivision of Research, Helix Opco, San Mateo, California, USA.
Lisa M McEwenDivision of Research, Helix Opco, San Mateo, California, USA.
Douglas StollerDivision of Cardiovascular Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Christopher N ChapmanDepartment of Pathology and Laboratory Medicine, St. Luke's University Health Network, Bethlehem, Pennsylvania, USA.
C Anwar A ChahalCenter for Inherited Cardiovascular Diseases, WellSpan Health, Ephrata, Pennsylvania, USA.
Daniel P JudgeDivision of Cardiology, Medical University of South Carolina, Charleston, South Carolina, USA.
Douglas A OlsonHealthPartners, Minneapolis, Minnesota, USA.
Joseph J GrzymskiUniversity of Nevada, School of Medicine, Reno, Nevada, USA; Renown Health, Reno, Nevada, USA.
Nicole L WashingtonDivision of Research, Helix Opco, San Mateo, California, USA.
William LeeDivision of Research, Helix Opco, San Mateo, California, USA.
Elizabeth T CirulliDivision of Research, Helix Opco, San Mateo, California, USA.
Shishi LuoDivision of Research, Helix Opco, San Mateo, California, USA.
Kelly Schiabor BarrettDivision of Research, Helix Opco, San Mateo, California, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lipoprotein(a) (Lp[a]) is a genetic and often unmeasured contributor to atherosclerotic cardiovascular disease (ASCVD) risk. In this study, Lp(a) was estimated from exome data by quantifying Kringle IV subtype 2 repeats alongside a single-nucleotide variant-based genetic risk score. This method was applied to a diverse cohort (N = 76,147) from the Helix Research Network. The method better identified individuals with high Lp(a) levels, especially among individuals not genetically similar to Europeans. High genetic risk for high Lp(a) level was correlated with earlier and more frequent ASCVD diagnoses. Those with high genetic Lp(a) were more likely to have ASCVD without traditional risk factors present.

Indexed as

cardiovascular diseaseclinical geneticsgenomicslipoprotein(a)

Identifiers

PMID40742365
PMCPMC12665494

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.